Bayer to 'accelerate' five drug candidates and expand on recent launches
This article was originally published in Scrip
Executive Summary
Following the recent launch of five new drugs, Bayer has outlined its plans to keep the momentum going. Five further drug candidates, currently in Phase I and II studies, are being "accelerated" with the aim of getting them into Phase III by 2015.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.